The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

Cannabinoid 1 receptor (CB1R) inverse agonists are emerging as a potential obesity therapy. However, the physiological mechanisms by which these agents modulate human energy balance are incompletely elucidated. Here, we describe a comprehensive clinical research study of taranabant, a structurally novel acyclic CB1 R inverse agonist. Positron emission tomography imaging using the selective CB1R tracer [F-18]MK-9470 confirmed central nervous system receptor occupancy levels (similar to 10%-40%) associated with energy balance/weight- loss effects in animals. In a 12-week weight-loss study, taranabant induced statistically significant weight loss compared to placebo in obese subjects over the entire range of evaluated doses (0.5, 2, 4, and 6 mg once per day) (p < 0.001). Taranabant treatment was associated with dose-related increased incidence of clinical adverse events, including mild to moderate gastrointestinal and psychiatric effects. Mechanism-of-action studies suggest that engagement of the CB1R by taranabant leads to weight loss by reducing food intake and increasing energy expenditure and fat oxidation

Focus op professie: Rapport Commissie Positionering Hoger Beroepsonderwijs

De onafhankelijke commissie ‘positionering hoger beroepsonderwijs’ heeft het rapport ‘Focus op professie’ aangeboden aan het bestuur van de Vereniging Hogescholen. Het rapport vormt belangrijke input voor de standpuntbepaling van de Vereniging Hogescholen ten aanzien van de toekomst van het hoger beroepsonderwijs, mede in het licht van de toekomstverkenning van het hoger onderwijs die minister Dijkgraaf van OCW in gang heeft gezet